JPMORGAN CHASE & CO - ENLIVEX THERAPEUTICS LTD ownership

ENLIVEX THERAPEUTICS LTD's ticker is ENLV and the CUSIP is M4130Y106. A total of 25 filers reported holding ENLIVEX THERAPEUTICS LTD in Q2 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.0%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of ENLIVEX THERAPEUTICS LTD
ValueSharesWeighting
Q3 2023$1,896
-69.7%
1,200
-49.6%
0.00%
Q2 2023$6,2572,379
+3204.2%
0.00%
Q1 2023$072
-26.5%
0.00%
Q4 2022$0
-100.0%
98
-91.5%
0.00%
Q1 2022$6,000
+100.0%
1,152
+85.5%
0.00%
Q1 2020$3,0006210.00%
Other shareholders
ENLIVEX THERAPEUTICS LTD shareholders Q2 2022
NameSharesValueWeighting ↓
ACT CAPITAL MANAGEMENT, LLC 15,000$68,0000.10%
Susquehanna International Group Ltd. 22,002$98,0000.02%
ARK Investment Management 331,001$1,658,0000.01%
Compagnie Lombard Odier SCmA 50,000$223,0000.01%
EDMOND DE ROTHSCHILD HOLDING S.A. 13,000$59,0000.00%
OSAIC HOLDINGS, INC. 400$2,0000.00%
BANK OF AMERICA CORP /DE/ 1,215$5,0000.00%
WELLS FARGO & COMPANY/MN 12,373$56,0000.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
GROUP ONE TRADING, L.P. 2,884$13,0000.00%
View complete list of ENLIVEX THERAPEUTICS LTD shareholders